Search

Displaying results 2151 - 2160 of 7540 in total
  1. Drug

    Cariprazine

    go.drugbank.com/drugs/DB06016
    ApprovedInvestigational

    Cariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … [L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochloride
  2. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-Cyclopropylmethylnoroxymorphone, N-Cyclopropylmethyl-14-hydroxydihydromorphinone
  3. Drug

    Almotriptan

    go.drugbank.com/drugs/DB00918
    Approved

    It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms … Almotriptan does not prevent migraine attacks.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Tafasitamab

    go.drugbank.com/drugs/DB15044
    ApprovedInvestigational

    relative to non-engineered anti-CD19 antibodies. … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.

  5. Drug

    Sulfacytine

    go.drugbank.com/drugs/DB01298
    Approved

    Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Sulfacytine is a competitive inhibitor of the enzyme dihydropteroate synthetase. … Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle.

    Synonyms: 1-ethyl N4-sulfanilylcytosin, 1-ethyl-N-sulfanilylcytosine
  6. Drug

    Ceruletide

    go.drugbank.com/drugs/DB00403
    Approved

    It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles. … Caerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin.

  7. Drug

    Alemtuzumab

    go.drugbank.com/drugs/DB00087
    ApprovedInvestigational

    Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. … [L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).

  8. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Satralizumab

    go.drugbank.com/drugs/DB15762
    ApprovedInvestigational

    [A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased

  10. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.